Rallybio Corp. (RLYB)
16.80
-0.03
(-0.18%)
USD |
NASDAQ |
Aug 24, 16:00
16.80
0.00 (0.00%)
After-Hours: 20:00
Rallybio Enterprise Value : -3.534M for Aug. 21, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| August 21, 2026 | -3.534M |
| August 20, 2026 | -4.754M |
| August 19, 2026 | -2.632M |
| August 18, 2026 | -3.852M |
| August 17, 2026 | -2.632M |
| August 14, 2026 | -2.685M |
| August 13, 2026 | -2.844M |
| August 12, 2026 | -4.808M |
| August 11, 2026 | -5.922M |
| August 10, 2026 | -4.701M |
| August 07, 2026 | -7.090M |
| August 06, 2026 | -6.930M |
| August 05, 2026 | -7.196M |
| August 04, 2026 | -8.151M |
| August 03, 2026 | -8.204M |
| July 31, 2026 | -8.310M |
| July 30, 2026 | -7.567M |
| July 29, 2026 | -8.151M |
| July 28, 2026 | -7.116M |
| July 27, 2026 | -6.294M |
| July 24, 2026 | -6.294M |
| July 23, 2026 | -5.869M |
| July 22, 2026 | -4.648M |
| July 21, 2026 | -3.109M |
| July 20, 2026 | -4.171M |
| Date | Value |
|---|---|
| July 17, 2026 | -5.710M |
| July 16, 2026 | -8.151M |
| July 15, 2026 | -7.249M |
| July 14, 2026 | -7.886M |
| July 13, 2026 | -8.522M |
| July 10, 2026 | -9.372M |
| July 09, 2026 | -8.841M |
| July 08, 2026 | -9.637M |
| July 07, 2026 | -9.690M |
| July 06, 2026 | -9.424M |
| July 02, 2026 | -8.920M |
| July 01, 2026 | -8.257M |
| June 30, 2026 | -7.939M |
| June 29, 2026 | 38.32M |
| June 26, 2026 | 38.00M |
| June 25, 2026 | 36.47M |
| June 24, 2026 | 37.58M |
| June 23, 2026 | 36.42M |
| June 22, 2026 | 37.63M |
| June 18, 2026 | 37.84M |
| June 17, 2026 | 37.58M |
| June 16, 2026 | 37.47M |
| June 15, 2026 | 37.47M |
| June 12, 2026 | 37.58M |
| June 11, 2026 | 37.58M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Q32 Bio, Inc. | 278.10M |
| Beam Therapeutics, Inc. | 2.168B |
| C4 Therapeutics, Inc. | 294.82M |
| Cullinan Therapeutics, Inc. | 1.067B |
| Arrowhead Pharmaceuticals, Inc. | 12.07B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 43.66M |
| Total Expenses (Quarterly) | -43.66M |
| EPS Diluted (Quarterly) | 7.531 |
| Earnings Yield | 46.50% |
| Normalized Earnings Yield | 14.75 |